This Article Full Text Full Text (PDF) All Versions of this Article: 36/2/205    most recent 01.STR.0000154923.27548.69v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hanley, D. Articles by Hacke, W. Search for Related Content PubMed PubMed Citation Articles by Hanley, D. Articles by Hacke, W.

(Stroke. 2005;36:205.)
© 2005 American Heart Association, Inc.

Advances in Stroke 2004

Critical Care and Emergency Medicine Neurology in Stroke

From the Division of Brain Injury Outcomes (D.F.H.), John Hopkins, Baltimore, Md; and the Department of Neurology (W.H.), University of Heidelberg, Germany.

Correspondence to Dr Daniel F. Hanley, John Hopkins, Division of Brain Injury Outcomes, 600 North Wolfe St., Jefferson Building, room 1-109, Baltimore, MD 21287. E-mail cmckenz4@jhmi.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Intracerebral Hemorrhage

 
Dramatic changes have occurred in the area of critical care and emergency stroke treatments of intracerebral hemorrhage (ICH). New data from three sponsored clinical trials: STICH (British National Health System-Medical Research Council), NOVO Seven (Novonordisk), and intraventricular hemorrhage (IVH) clot lysis (FDA Orphan Drug Program)¹ were presented at the 29^th International Stroke Meeting² and the World Stroke Congress. Several avenues of approach to the problem of ICH are opening. Although the data from these trials are now under peer review, the initial presentations have demonstrated several principles that seem clear. First, craniotomy (though not better than initial medical management) is safe and not worse than initial medical management. Second, deterioration occurs frequently (25% of the time) in the initial days after ICH. Deterioration was treated with surgery. Third, a strategy of emergent clot stabilization is safe and shows trends toward efficacy in the NOVO Seven dose finding study.² Finally, catheter-assisted removal of blood clot from the obstructed ventricular system in IVH can be accomplished safely with low dose recombinant tissue plasminogen activator (rtPA).³ These trial results suggest that the basic elements of aneurysm care are now being applied to ICH care: emergent stabilization of the bleeding site, followed by removal of blood and management of cranial vault mechanics. Data are now beginning to support that applying these principles leads to improvement in mortality and morbidity.

We hope that the robustness of the peer-reviewed data continues to point to the value of emergent intervention for the ICH patient. New sponsored . . . [Full Text of this Article]